Navigation Links
Genaera Corporation Announces Second Quarter Financial Results
Date:8/11/2008

PLYMOUTH MEETING, Pa., Aug. 11 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR) today announced its financial results for the three- and six-month periods ended June 30, 2008. The net loss for the three-month period ended June 30, 2008 was $4.8 million, or $(0.27) per share basic and diluted, as compared to a net loss of $2.0 million, or $(0.11) per share basic and diluted, for the three-month period ended June 30, 2007. The net loss for the six-month period ended June 30, 2008 was $9.0 million, or $(0.52) per share basic and diluted, as compared to a net loss of $6.2 million, or $(0.35) per share basic and diluted, for the six-month period ended June 30, 2007.

Genaera's research and development expenses for the three- and six-month periods ended June 30, 2008 were $3.5 million and $7.4 million, respectively, compared to $3.1 million and $6.6 million, respectively, for the same periods in 2007. The increase was primarily due to increases in research and clinical costs related to the trodusquemine (MSI-1436) program for the treatment of obesity and type 2 diabetes and increases in stock-based compensation expense. These increases were partially offset by decreases in manufacturing and personnel costs associated with the MSI-1436 program and decreases in clinical, manufacturing, research and personnel expenses as a result of the termination of the squalamine program for the treatment of wet age-related macular degeneration and the LOMUCIN(TM) program for the treatment of cystic fibrosis in 2007.

Genaera's general and administrative expenses for the three- and six-month periods ended June 30, 2008 were $1.4 million and $3.6 million, respectively, compared to $1.6 million and $3.1 million, respectively, for the same
'/>"/>

SOURCE Genaera Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Genaera Elects New Board Member and Announces Executive Appointments
2. Genaera to Present at Biotech 2007 and BIO InvestorForum
3. Genaera Corporation Announces Third Quarter Financial Results
4. Genaera Corporation to Participate in Diabetes and Obesity Panel at RBC Capital Markets Healthcare Conference
5. Genaera Corporation Announces 2007 Financial Results
6. Genaera Corporation Announces First Quarter Financial Results
7. Genaera Corporation to Present at BIO Business Forum
8. Genaera Corporation Elects Paul K. Wotton to Board of Directors
9. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
10. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
11. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... , March 6, 2015 ...   2011 von der Assistance Publique - ... initiiert., Sie ist eine französische, gemeinschaftliche, randomisierte ... Patienten rekrutiert wurden. Verglichen werden Patienten mit ... Yttrium-90 Harz-Mikrosphären oder Sorafenib behandelt wurden. Die ...
(Date:3/5/2015)... FRANCISCO , March 5, 2015  Twelve patients ... six-way kidney paired donation transplant at California Pacific Medical ... Physicians here believe this procedure will be the largest ... Coast and the largest conducted in the 44-year history ... today and tomorrow began with an altruistic donor who ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 LifeCell Dx ... be able to get an Advanced Semen Analysis before ... blaming and guessing are all risk factors for struggling ... woman is the source of the infertility. Infertility is ... Dx has the simplest, least complicated and inexpensive ...
(Date:3/5/2015)... 05, 2015 BioPlus Specialty Pharmacy (BioPlus) ... of Vice President of Managed Care. In this role, ... one of the nation’s leading specialty pharmacies. , Damm, ... years of specialty pharmacy and biotech experience to his ... Pharmaceuticals, Vertex Pharmaceuticals, and Pfizer. Prior to working in ...
Breaking Biology Technology:Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 2Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 3Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 4Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 5Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 6Altruistic donor starts large West Coast single-center kidney paired donation at CPMC 2Altruistic donor starts large West Coast single-center kidney paired donation at CPMC 3Altruistic donor starts large West Coast single-center kidney paired donation at CPMC 4LifeCell Dx Offers New Option to Veterans with Infertility 2LifeCell Dx Offers New Option to Veterans with Infertility 3BioPlus Specialty Pharmacy Announces Hiring of New Vice President of Managed Care: Jamie Damm 2
... February 9 ,Shire plc (LSE: SHP, NASDAQ: SHPGY ), ... Thursday 19 February 2009. , , Results press ... 07:00 EST, Investor meeting and conference call time: ... Investor & Analyst meeting and conference call: , ...
... Molecular and cellular biologists have made tremendous ... individual genes, proteins, and pathways. Researchers at the ... to expand that understanding by putting the pieces ... of chemical and biological engineering, developed computer models ...
... Diffusion Pharmaceuticals LLC, a clinical-stage drug development ... today announced the completion of a $2.9 million ... company,s overall growth and clinical programs for its ... (TSC). In addition, David G. Kalergis, Chief Executive ...
Cached Biology Technology:Full Year 2008 Results Date Notification - 19 February 2008 2Mathematical models reveal how organisms transcend the sum of their genes 2Diffusion Pharmaceuticals Announces Completion of a $2.9 Million Private Placement and Company Presentations at Upcoming Industry Conferences in Geneva, Switzerland and Naples, Florida 2Diffusion Pharmaceuticals Announces Completion of a $2.9 Million Private Placement and Company Presentations at Upcoming Industry Conferences in Geneva, Switzerland and Naples, Florida 3
(Date:2/5/2015)...  It is gratifying to see that the Obama ... science as a means to better understand human biology, ... was honored to participate in today,s White House event ... Since the 1980s my teams have been ... sequenced genome of a free living organism, the first ...
(Date:1/22/2015)... the leading source of biometrics industry news, interviews and thought ... "When we launched FindBiometrics 12 years ago the industry ... and CEO of FindBiometrics. "Now it,s maturing very quickly. More ... on a very broad scale.  We are known for providing ...
(Date:1/22/2015)... N.C. , Jan. 16, 2015  A man-made form ... memory and other mental capabilities in adults with mild ... pilot study led by researchers at Wake Forest Baptist ... adults diagnosed with amnesic mild cognitive impairment (MCI) or ...
Breaking Biology News(10 mins):J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3
... method to mine existing scientific data may provide a ... environment and biological processes, say researchers at the Stanford ... Harvard Medical School. Like panning for gold, they used ... of unrelated information - in this case, gene expression ...
... the Ohio State University Comprehensive Cancer Center say that ... cancer in mice. The discovery offers new insight into ... and at the same time underscores the powerful role ... cell signaling pathways active in carcinogenesis. , "To ...
... warming to the recent extinction of dozens of amphibian ... large phenomena that may affect broad regions, many animal ... State University. , A study being published Thursday in ... change created favorable conditions for a pathogenic fungus in ...
Cached Biology News:Stanford/Packard scientist's data-mining technique strikes genetic gold 2Stanford/Packard scientist's data-mining technique strikes genetic gold 3Single microRNA causes cancer in transgenic mouse 2Single microRNA causes cancer in transgenic mouse 3Extinctions linked to climate change 2Extinctions linked to climate change 3
The Programmable MP-5000P-F Power Supply can be applied for any Microfluidic application....
...
Handy 100V Power Supply is Low-cost, compact and lightweight. Easy to operate - either 50 or 100 VDC is selectable as the output voltage. These voltages are sufficient for ordinary electrophoresis....
... Science Smart Minis 150V power supply (Cat. ... power supplies designed to meet most electrophoresis ... use unit. The Minis 150V power supply ... Minis Power Supply is designed for individuals ...
Biology Products: